N
%
Patients
2,630
100
Sex
Male
1,275
48.5
Female
1,355
51.5
Age (years)
18–29.9
141
5.4
30–39.9
300
11.4
40–49.9
437
16.6
50–59.9
604
23.0
60–69.9
649
24.7
70–79.9
411
15.6
>80
88
3.3
Type of surgery
Primary
2,141
81.4
Second
489
18.6
Craniotomy
Resection
2,556
97.2
Open biopsy
74
2.8
Main histology
High-grade glioma (HGG)
830
31.6
Meningioma
693
26.3
Metastases
449
17.1
Low-grade glioma (LGG)
289
11.0
Schwannoma
73
2.8
Primary CNS-lymphoma
51
1.9
CNS hemangioblastoma
39
1.5
Cavernous hemangioma
38
1.4
Pituitary adenoma
8
0.3
Others
160
6.1
Perioperative Craniotomy Routines
A consultant anesthetist should see all craniotomy patients preoperatively. Elderly patients (>70 years) and patients on multiple medications should routinely also seen by consultant internist, to optimize the general medical condition and medications. At our institution, a second-generation cephalosporin is administered intravenously at initiation of surgery and continued every 90 min until the case is completed or the maximum daily dose of 8 g is reached. For long cases, erythromycin or a third-generation cephalosporin is started after the maximum daily dose of a second-generation cephalosporin is reached and continued until completion of the case. Antibiotics are not routinely used in the postoperative phase.
Incidence of Craniotomies
First-time craniotomies with primary resection were performed in 2,073 cases, 483 cases were reoperations with repeated resection, and 74 cases were open biopsies. Thus, the incidence of first-time craniotomy for a brain tumor was 12.8/100,000 inhabitants per year and for a repeat resection 3.0/100,000 inhabitants per year.
Postoperative Infection Requiring Recraniotomy
A total of 39 patients (1.5 %) were reoperated for deep postoperative infection (Table 20.2). Of these infections, 23 (59.0 %) were extradural (ED), 6 (15.4 %) intradural (ID), and 10 (25.6 %) were both intra- and extradural.
Table 20.2
Patients reoperated for postoperative infection (n = 39)
Age | Sex | ASA | ECOG | Immune compromise | Histologya | Locationb | Time to reop. (days)c | Outcomed |
---|---|---|---|---|---|---|---|---|
18 | M | 2 | 2 | – | HGG | ED | 16 | NAD |
40 | M | 2 | 3 | – | HGG | ED | 46 | NAD |
57 | M | NA | 1 | – | HGG | ED | 20 | NAD |
59 | M | 3 | 3 | – | HGG | ED | 307 | NAD |
64 | M | 3 | 3 | – | HGG | ED | 49 | Death |
69 | M | 3 | 3 | Diabetes | HGG | ED | 80 | Major |
70 | M | 2 | 1 | – | HGG | ED | 20 | NAD |
70 | F | 2 | 1 | – | HGG | ID | 25 | NAD |
34 | M | 2 | 2 | HIV | Lymfoma | ED | 667 | NAD |
26 | F | 1 | 1 | – | Meningioma | ED | 71 | NAD |
33 | F | 2 | 1 | – | Meningioma | ED | 119 | NAD |
38 | M | 2 | 1 | – | Meningioma | ED | 248 | NAD |
40 | F | 1 | 1 | – | Meningioma | ED | 270 | NAD |
42 | F | 1 | 1 | – | Meningioma | ED/ID | 25 | Minor |
49 | M | 2 | 1 | – | Meningioma | ED/ID | 29 | NAD |
51 | M | 3 | 1 | – | Meningioma | ID | 31 | NAD |
53 | F | 2 | 1 | – | Meningioma | ED | 42 | NAD |
55 | M | 2 | 1 | – | Meningioma | ED | 18 | NAD |
56 | M | 3 | 1 | Diabetes | Meningioma | ID | 45 | NAD |
56 | F | NA | 1 | – | Meningioma | ED/ID | 38 | Minor |
56 | M | 2 | 1 | – | Meningioma | ED | 35 | NAD |
58 | M | 3 | 1 | – | Meningioma | ED | 59 | NAD |
64 | M | 2 | 1 | – | Meningioma | ID
![]() Stay updated, free articles. Join our Telegram channel![]() Full access? Get Clinical Tree![]() ![]() ![]() |